{ "schema_version": 1, "kind": "condition", "id": "hyperprolactinaemia-referral", "name": "Hyperprolactinaemia (Evaluation & Management)", "category": "chronic", "sources": "Endocrine Society Guideline on Pituitary Tumors 2011 · Egyptian National Drug Formulary - Endocrine System 2024 (bromocriptine monograph)", "review_status": "reviewed", "verified_against": "Endocrine Society Guideline on Pituitary Tumors 2011 · Egyptian National Drug Formulary - Endocrine System 2024 (bromocriptine monograph) · Hyperprolactinaemia (Evaluation & Management) - disease-level clinical article (hyperprolactinaemia-referral-full.txt)", "verified_date": "2026-08", "treatments": [ { "id": 963, "generic": "Cabergoline", "line": 1, "is_adjunct": false, "form": "oral.solid", "strength_mg": 0.5, "adult_dose": "0.5 mg weekly (administered as 0.25 mg twice weekly), titrate by 0.5 mg/week monthly up to max 4.5 mg/week based on prolactin levels", "adult_duration": "long-term", "dose_source": "Endocrine Society Guideline on Pituitary Tumors 2011", "rationale": "Dopamine agonist that suppresses prolactin secretion by stimulating pituitary D2 receptors; first-line therapy for hyperprolactinaemia given its efficacy and tolerability advantage over bromocriptine, started only after pregnancy, hypothyroidism, and drug-induced causes have been excluded.", "cautions": [ "Cabergoline is the first-line dopamine agonist, with superior efficacy and tolerability over bromocriptine.", "Exclude pregnancy, hypothyroidism, and drug-induced causes (antipsychotics, metoclopramide) before starting.", "Perform baseline echocardiogram if high doses (>2 mg/week) or prolonged high-dose therapy are used due to risk of cardiac valvulopathy." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "Specialist pediatric endocrinology management", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [ { "trade_name": "CABERGOLACTO 0.5 MG 2 TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "IDI > NOVELL PHARMA", "price_egp": 36.0, "pack_count": 2, "unit_price": 18.0, "strength_mg": 0.5, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "CABERGLOBE 0.5 MG 2 TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "EGPI > GLOBE INTERNATIONAL PHARMACEUTICALS", "price_egp": 45.0, "pack_count": 2, "unit_price": 22.5, "strength_mg": 0.5, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "MARVIGOLINE 0.5 MG 2 TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "RAMEDA", "price_egp": 66.0, "pack_count": 2, "unit_price": 33.0, "strength_mg": 0.5, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "CABROSTINEX 0.5 MG 8 TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "MEDIZEN PHARMACEUTICAL INDUSTRIES > ROTABIOGEN", "price_egp": 339.0, "pack_count": 8, "unit_price": 42.38, "strength_mg": 0.5, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "GOLINOTECH 0.5 MG 2 TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "EUROPEAN EGYPTIAN PHARM. IND. > PHARMA-TECH", "price_egp": 103.0, "pack_count": 2, "unit_price": 51.5, "strength_mg": 0.5, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "DOSTILACT 0.5 MG 2 TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "ATCO PHARMA > OMEGA PHARMA OPCI", "price_egp": 105.0, "pack_count": 2, "unit_price": 52.5, "strength_mg": 0.5, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "DOSTINEX 0.5 MG 2 TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "PFIZER", "price_egp": 172.0, "pack_count": 2, "unit_price": 86.0, "strength_mg": 0.5, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "DELCABRIN 0.5 MG 2 SCORED TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "EGPI > HEALTH WELL EGYPT", "price_egp": 105.0, "pack_count": null, "unit_price": null, "strength_mg": 0.5, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null } ], "condition_id": "hyperprolactinaemia-referral" }, { "id": 965, "generic": "Referral & safety-netting (no drug therapy)", "line": 1, "is_adjunct": false, "form": null, "strength_mg": null, "adult_dose": null, "adult_duration": null, "dose_source": "Hyperprolactinaemia (Evaluation & Management) - disease-level clinical article (hyperprolactinaemia-referral-full.txt)", "rationale": "Carries the referral criteria and warning signs for this condition, which apply whichever treatment is chosen.", "cautions": [ "RED FLAG - Pituitary apoplexy is an endocrine emergency presenting with sudden headache and visual disturbances, requiring urgent MRI and neurosurgical evaluation." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": null, "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [], "condition_id": "hyperprolactinaemia-referral" }, { "id": 964, "generic": "Bromocriptine", "line": 2, "is_adjunct": false, "form": "oral.solid", "strength_mg": 2.5, "adult_dose": "1.25 mg at bedtime with food, titrate to 2.5 mg twice to three times daily", "adult_duration": "long-term", "dose_source": "Egyptian National Drug Formulary - Endocrine System 2024 (bromocriptine monograph)", "rationale": "Older dopamine agonist with the same prolactin-suppressing mechanism as cabergoline, preferred specifically when pregnancy is desired because of its longer safety track record in that setting.", "cautions": [ "Bromocriptine is the preferred dopamine agonist if pregnancy is desired, due to its extensive safety history.", "Nausea, postural hypotension, and dizziness are common during dose initiation." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "Specialist use only", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [ { "trade_name": "PARLODEL 2.5MG 20 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "NOVARTIS", "price_egp": 27.6, "pack_count": 20, "unit_price": 1.38, "strength_mg": 2.5, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "BROMOCRIPTINE 2.5 MG 30 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "OCTOBER PHARMA", "price_egp": 66.0, "pack_count": 30, "unit_price": 2.2, "strength_mg": 2.5, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "LACTODEL 2.5MG 20 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "AMOUN", "price_egp": 72.0, "pack_count": 20, "unit_price": 3.6, "strength_mg": 2.5, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "DOPAGON 2.5MG 20 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "MEMPHIS", "price_egp": 94.0, "pack_count": 20, "unit_price": 4.7, "strength_mg": 2.5, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null } ], "condition_id": "hyperprolactinaemia-referral" } ] }